Dizal Jiangsu Pharmaceutical Co Ltd
SSE:688192
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Realty Income Corp
NYSE:O
|
Real Estate
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
27.15
52.5
|
Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
Abbvie Inc
NYSE:ABBV
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Realty Income Corp
NYSE:O
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one Dizal Jiangsu Pharmaceutical Co Ltd stock under the Base Case scenario is 27.06 CNY. Compared to the current market price of 35.99 CNY, Dizal Jiangsu Pharmaceutical Co Ltd is Overvalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Dizal Jiangsu Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling Dizal Jiangsu Pharmaceutical Co Ltd based on its intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Price Target |
Loading
|
Revenue Forecast |
|
Operating Income Forecast |
|
Earnings Forecast |
|
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Dizal Jiangsu Pharmaceutical Co Ltd
Balance Sheet Decomposition
Dizal Jiangsu Pharmaceutical Co Ltd
Current Assets | 910.4m |
Cash & Short-Term Investments | 748.2m |
Receivables | 85.5m |
Other Current Assets | 76.6m |
Non-Current Assets | 586m |
PP&E | 104.8m |
Intangibles | 462m |
Other Non-Current Assets | 19.2m |
Current Liabilities | 448.4m |
Accounts Payable | 108.9m |
Accrued Liabilities | 57.5m |
Short-Term Debt | 201.8m |
Other Current Liabilities | 80.2m |
Non-Current Liabilities | 199.3m |
Long-Term Debt | 187.2m |
Other Non-Current Liabilities | 12.1m |
Earnings Waterfall
Dizal Jiangsu Pharmaceutical Co Ltd
Revenue
|
172.6m
CNY
|
Cost of Revenue
|
-6.2m
CNY
|
Gross Profit
|
166.4m
CNY
|
Operating Expenses
|
-1.3B
CNY
|
Operating Income
|
-1.1B
CNY
|
Other Expenses
|
10.7m
CNY
|
Net Income
|
-1.1B
CNY
|
Free Cash Flow Analysis
Dizal Jiangsu Pharmaceutical Co Ltd
CNY | |
Free Cash Flow | CNY |
Profitability Score
Profitability Due Diligence
Dizal Jiangsu Pharmaceutical Co Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
Dizal Jiangsu Pharmaceutical Co Ltd's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Dizal Jiangsu Pharmaceutical Co Ltd's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Score
Dizal Jiangsu Pharmaceutical Co Ltd's solvency score is 72/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Dizal Jiangsu Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for Dizal Jiangsu Pharmaceutical Co Ltd is 55.08 CNY with a low forecast of 54.54 CNY and a high forecast of 56.7 CNY.
Shareholder Yield
Current shareholder yield for Dizal Jiangsu Pharmaceutical Co Ltd is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Price
Dizal Jiangsu Pharmaceutical Co Ltd
Average Annual Return | -1.83% |
Standard Deviation of Annual Returns | 11.24% |
Max Drawdown | -52% |
Market Capitalization | 14.7B CNY |
Shares Outstanding | 408 151 400 |
Percentage of Shares Shorted |
N/A
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Dizal (Jiangsu) Pharmaceutical Co., Ltd. engages in the discovery, development, and commercialization of innovative medicines. The company is headquartered in Shanghai, Shanghai and currently employs 328 full-time employees. The company went IPO on 2021-12-10. The firm focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The firm is still in the R&D stage.
Contact
IPO
Employees
Officers
The intrinsic value of one Dizal Jiangsu Pharmaceutical Co Ltd stock under the Base Case scenario is 27.06 CNY.
Compared to the current market price of 35.99 CNY, Dizal Jiangsu Pharmaceutical Co Ltd is Overvalued by 25%.